scPharmaceuticals (NASDAQ:SCPH) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of scPharmaceuticals (NASDAQ:SCPH) in a report published on Monday morning,Benzinga reports. The firm currently has a $18.00 target price on the stock.

Separately, Craig Hallum dropped their target price on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, November 14th.

scPharmaceuticals Stock Down 2.1 %

Shares of scPharmaceuticals stock opened at $3.21 on Monday. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. scPharmaceuticals has a 1 year low of $3.08 and a 1 year high of $6.20. The firm’s 50-day moving average is $3.40 and its two-hundred day moving average is $3.99. The stock has a market cap of $160.63 million, a price-to-earnings ratio of -1.69 and a beta of 0.11.

Institutional Trading of scPharmaceuticals

Several hedge funds have recently modified their holdings of SCPH. Suvretta Capital Management LLC purchased a new position in shares of scPharmaceuticals in the 3rd quarter valued at approximately $9,343,000. Rubric Capital Management LP raised its position in shares of scPharmaceuticals by 35.5% in the 3rd quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock valued at $21,774,000 after purchasing an additional 1,250,000 shares during the last quarter. King Luther Capital Management Corp raised its position in shares of scPharmaceuticals by 28.4% in the 4th quarter. King Luther Capital Management Corp now owns 2,857,910 shares of the company’s stock valued at $10,117,000 after purchasing an additional 632,120 shares during the last quarter. Rice Hall James & Associates LLC raised its position in shares of scPharmaceuticals by 59.2% in the 4th quarter. Rice Hall James & Associates LLC now owns 989,635 shares of the company’s stock valued at $3,503,000 after purchasing an additional 367,970 shares during the last quarter. Finally, Stonepine Capital Management LLC raised its position in shares of scPharmaceuticals by 84.7% in the 3rd quarter. Stonepine Capital Management LLC now owns 778,874 shares of the company’s stock valued at $3,552,000 after purchasing an additional 357,171 shares during the last quarter. 89.52% of the stock is owned by hedge funds and other institutional investors.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.